CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions

Sponsor
CDx Diagnostics (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT03214835
Collaborator
Rambam Health Care Campus (Other)
0
2
21.9

Study Details

Study Description

Brief Summary

The study will take place at Rambam medical center, department of Otolaryngology Head and Neck Surgery, for two years. Patients suspected of LPR or laryngeal l tumor and are candidate for laryngeal or hypopharyngeal biopsies will be recruited.

Condition or Disease Intervention/Treatment Phase
  • Device: Endo CDx Brush biopsy
N/A

Detailed Description

First- all patients visiting our clinic with laryngeal complaints suspicious for either LPR or laryngeal tumor will fill the RSI questionnaire. Then fiberoptic examination will be performed by a laryngologist that will complete the RFS score.

Patients with suspicious lesions will be referred for TFL standard biopsy and CDx brush biopsy in order to determine whether the lesions are malignant or benign. The pathologic diagnosis of invasive carcinoma from a TFL biopsy is considered equivalent to the pathology results from a direct laryngoscopy biopsy. All patients with benign pathology or carcinoma in-situ (CIS) on TFL biopsy will be referred for subsequent direct laryngoscopy (DL) for definitive diagnosis. At the time of the DL biopsy will include also another CDx brush smear. Patients with benign-appearing lesions will be taken for lesion removal and biopsy.Before removal of the lesion a CDx brush smear will be collected.

All the participants suspected of LPR will have: PHmetry with Manometry andCDx brush biopsy.All relevant demographic and clinical data will be retrieved for analysis.

CDx biopsies will be an addition to the routine management of the patients in the diagnosis and follow-up of laryngeal lesions and LPR and will not replace the standard regimen.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Screening
Official Title:
CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions
Anticipated Study Start Date :
Feb 1, 2018
Anticipated Primary Completion Date :
Aug 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brush biopsy for laryngeal lesion

Brush biopsy of the larynx - in addition to the standard biopsy

Device: Endo CDx Brush biopsy
In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.

Experimental: Brush biopsy for LPR

Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)

Device: Endo CDx Brush biopsy
In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.

Outcome Measures

Primary Outcome Measures

  1. Efficacy of EndoCDx brush [3 months]

    Efficacy of EndoCDx brush biopsy as a diagnostic tool for laryngeal lesions compared to cup forceps biopsy and a diagnostic tool for LPR compared to double probe PH monitoring

Secondary Outcome Measures

  1. Assessment of pain [6 months]

    Assessment of pain during EndoCDx brush biopsy under local anesthesia by Visual Analog Score for pain

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 or over

  • patients suspected to suffer from LPR

  • Patients with laryngeal/hypopharyngeal lesions.

Exclusion Criteria:
  • Patient refusal

  • Patients with anatomical variants which precludes biopsy taking.

  • Patients with allergy to lidocain-based local anesthesia agents.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • CDx Diagnostics
  • Rambam Health Care Campus

Investigators

  • Principal Investigator: Jacob Cohen, MD, Rambam Health Care Campus

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CDx Diagnostics
ClinicalTrials.gov Identifier:
NCT03214835
Other Study ID Numbers:
  • CDx Laryngeal and LPR Study
First Posted:
Jul 12, 2017
Last Update Posted:
Jul 20, 2020
Last Verified:
Jul 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CDx Diagnostics
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2020